Bio Pharma Dive
NOVEMBER 3, 2022
In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discussed how startups can navigate a challenging market as well as possible ripple effects from the new U.S. drug pricing law.
Pharmaceutical Technology
NOVEMBER 2, 2022
Pfizer has reported a 6% decline in revenue to $22.6bn in the third quarter (Q3) of 2022 as against $24bn in the same quarter last year. In the quarter, revenues rose 2% operationally on omitting contributions from Covid-19 therapies, Paxlovid and Comirnaty. Reduction in revenues from Comirnaty outside the US and reduced revenues for some Comirnaty-linked manufacturing works carried out on behalf of BioNTech, Xeljanz and Sutent worldwide were the key drivers that contributed to the revenue dec
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 31, 2022
Rheumatoid arthritis affects 1 in 100 people worldwide. It causes inflamed, painful and swollen joints, often in the hands and wrists, and can lead to loss of joint function as well as chronic pain and joint deformities and damage. What causes this condition has been unknown. [link] In our recently published study, my colleagues and […].
Pharma Times
NOVEMBER 4, 2022
Treatment will assist young people and children with symptoms of mild-to-moderate anxiety
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
NOVEMBER 1, 2022
To some analysts, the recent acquisitions of Akouos and AGTC, as well as Astellas’ equity investment in Taysha, are a positive signal for an area of drug research that’s been “in investors' penalty box for much of 2022.
Pharmaceutical Technology
OCTOBER 31, 2022
Hoffmann-La Roche (Roche Canada) has received approval from Health Canada for Actemra IV (tocilizumab for injection) vials to treat Covid-19 patients. The treatment is indicated for adult Covid-19 patients who are on systemic corticosteroids and need additional oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 2, 2022
The study evaluated the safety, efficacy and immunogenicity of AELIX’s HIV vaccine
Bio Pharma Dive
NOVEMBER 4, 2022
Competition is increasing behind newly approved drugs from Roche and J&J, while the long-term benefit of gene therapies for chronic blood disorders is being put to the test.
Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Massachusetts Institute of Technology (MIT)’s Computer Science and Artificial Intelligence Laboratory (CSAIL) researchers have developed a system called ‘series elastic end effectors’ (SEED) that enable robots to use grabbed tools correctly and successfully. It was developed in partnership with the American Toyota Research Institute (a technology research unit of Toyota).
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 2, 2022
Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition. [link] In a new study, published Thursday (27 October) in the journal Science, researchers identified a previously unknown class of DNA-damaging molecules, or genotoxins, […].
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
NOVEMBER 1, 2022
CamPROBE may save vital time and money while reducing the risk of infection
Bio Pharma Dive
NOVEMBER 3, 2022
With public offerings difficult to pull off, Artiva is focusing its energy on a cancer drug deal with the German biotech.
Pharmaceutical Technology
NOVEMBER 1, 2022
FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. The Excellence Rankings celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognise the people and companies that are driving change.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
Porous particles of silica made from purified sand could one day play a role in attempts to lose weight. Past clinical trials have already produced promising results, but the actual weight-lowering mechanism behind the potential treatment has been poorly understood. [link] To sift out the key variables, researchers have now tested a range of silica […].
Pharma Times
NOVEMBER 3, 2022
Grant from Innovate UK SMART awarded to accelerate clinical trial progress
Bio Pharma Dive
OCTOBER 31, 2022
Bringing more diversity to clinical trials is a slow process and it takes time to get right. Learn how Worldwide Clinical Trials can diversify the reach of your orphan drug trial.
Pharmaceutical Technology
NOVEMBER 2, 2022
Small molecule approvals are on the decline in China. According to GlobalData’s Drugs Intelligence Database, from 2020 to 2022, the number of innovator small molecule approvals in China shrank by 21%. However, over the same period, approvals for innovator small molecules treating rare diseases rose by 22%, giving hope to rare disease patients. According to the GlobalData’s Drug Database, the number of innovator small molecule approvals for rare diseases rose steadily over three years, from three
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 3, 2022
In a bid to control the microbial quality of pharmaceutical products, the Indian Pharmacopoeia Commission (IPC) has come out with a draft amendment to microbial contamination in non-sterile products in Indian Pharmacopoeia (IP) 2022. The new draft amendment released by IPC on October 26, 2022 introduced changes to enumeration of aerobic microorganisms present in the […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
NPR Health - Shots
NOVEMBER 3, 2022
The updated recommendations seek to course correct after guidelines from 2016 were criticized for harshly limiting access to needed pain medication. (Image credit: Jose M.
Bio Pharma Dive
OCTOBER 31, 2022
For the second time this year, the agency has put off a decision on Amicus' therapy for Pompe disease. European regulators are also reviewing the treatment and could soon issue an opinion.
Pharmaceutical Technology
NOVEMBER 1, 2022
Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. The merged business will use human milk biology for the treatment of Gut-Brain Axis (GBA) disorders. The merger reflects a $136m pre-money equity price and is anticipated to offer up to $178.8m in cash held in trust to Intrinsic. .
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 1, 2022
As drug companies have embarked on an initiative to launch affordable medicines for rare diseases in India, experts have called for using pharmacogenetics to develop treatments and whole genome sequencing to identify etiologies. “Although rare diseases have a huge impact when taken together, there is a significant gap between clinical interventions and basic research.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
NPR Health - Shots
NOVEMBER 2, 2022
It could amount to the last round of huge settlements after years of litigation over the industry's role in an overdose crisis linked to more than 500,000 deaths in the U.S. over the past two decades.
Bio Pharma Dive
NOVEMBER 3, 2022
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.
Pharmaceutical Technology
NOVEMBER 1, 2022
The number one mechanism of action (MoA) for the Alzheimer’s disease (AD) pipeline is the inhibition of amyloid plaque formation. However, according to new research by the University of Cincinnati, amyloid plaques may not be the major cause of AD as previously thought—so are they the best target? AD is the leading cause of dementia, which is an umbrella term for a series of syndromes that can lead to memory loss, cognitive decay and behavioural change.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
High optimism prevails on the implementation of QR code which would aid faster traceability through the supply chain among Indian pharma. Nakul Pasricha, president, Authentication Solution Providers’ Association (ASPA), noted that a sharp spike was observed in the number of counterfeiting incidents related to pharma and medical products estimated as high as at 47 percent. […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
OCTOBER 31, 2022
Information from 17 existing studies was reviewed, involving 91 million people
Bio Pharma Dive
NOVEMBER 2, 2022
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
Pharmaceutical Technology
OCTOBER 31, 2022
The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 billion in 2031, at a compound annual growth rate (CAGR) of 4.4%. Major drivers of growth in the OA market over the forecast period include the launch of new biologic therapies as well as the launch of drugs with novel mechanisms of action (MOAs) and disease-modifying effects.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 1, 2022
“Zombie cells” that contribute to age-related diseases also help heal damaged tissues, so wiping them out could come with major downsides, a new study suggests. The zombies, scientifically known as “senescent” cells, are cells that stop multiplying due to damage or stress but don’t die, according to the National Institute on Aging.
Expert insights. Personalized for you.
362 
Let's personalize your content